Brem EA, Shieh K, Juarez D, et al. A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy. Blood Neoplasia. 2024;1(4):100036.
Brem EA, Shieh K, Juarez D, et al. A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy. Blood Neoplasia. 2024;1(4):100036. // Blood Neoplasia. – URL: https://www.sciencedirect.com/science/article/pii/S2950328026000695?dgcid=rss_sd_all
Brem EA, Shieh K, Juarez D, et al. A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy. Blood Neoplasia. 2024;1(4):100036. Blood Neoplasia. https://www.sciencedirect.com/science/article/pii/S2950328026000695?dgcid=rss_sd_all
“Brem EA, Shieh K, Juarez D, et al. A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy. Blood Neoplasia. 2024;1(4):100036.” Blood Neoplasia.
@article{article97590,
title = {Brem EA, Shieh K, Juarez D, et al. A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy. Blood Neoplasia. 2024;1(4):100036.},
journal = {Blood Neoplasia},
url = {https://www.sciencedirect.com/science/article/pii/S2950328026000695?dgcid=rss_sd_all}
}
Nature Reviews Cancer, Published online: 19 November 2026; doi:10.1038/s41568-026-01001-2 In this Journal Club, Chien-Han Kao and Ruey-Hwa Chen discuss a study showing that tumours use both de novo purine biosynthesis and purine salvage...
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01779-2 Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01786-3 Postoperative timing effects on AI-based resection-cavity segmentation in glioma: multi-site evaluation and relevance assessment